Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : Fosun-BioNTech COVID-19 vaccine completes China regulator review - media

07/14/2021 | 11:14pm EDT

SHANGHAI, July 15 (Reuters) - Chinese regulators have completed an expert review of a COVID-19 mRNA vaccine developed by Germany's BioNTech and Fosun Pharma and the shot is in the administration review stage, Caixin reported, citing the Chinese company.

China hasn't approved any COVID-19 vaccine developed overseas but greenlighted several domestic brands, administering 1.4 billion doses so far, or two-fifths of the global total of 3.47 billion doses.

BioNTech Chief Executive Ugur Sahin said in April he expected its COVID-19 vaccine would win approval from the Chinese authorities "by June at the latest."

BioNTech and Fosun did not immediately reply to Reuters' requests for comment.

The vaccine is on track to begin trial production in China at the end of August, Caixin cited Fosun Pharma chairman Wu Yifang as saying at a shareholders' meeting on Wednesday.

It said the vaccine would be used as a booster shot for people who have received vaccines using inactivated viruses.

These are vaccines that use a coronavirus that cannot replicate in human cells and include Sinovac's COVID-19 shot. (Reporting by David Stanway; Editing by Raju Gopalakrishnan)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 2.07% 58.7 End-of-day quote.8.72%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about SINOVAC BIOTECH LTD.
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/09SINOVAC BIOTECH : Says its New Research Shows Third Dose if its COVID-19 Vaccine..
MT
09/09SINOVAC BIOTECH : New Research on SINOVAC's COVID-19 Vaccine Shows Third Dose Mo..
BU
09/08SINOVAC BIOTECH : Announces COVID-19 Vaccine Approved for Emergency Use in Chile..
BU
09/07SINOVAC BIOTECH : Mixing CanSinoBIO, Sinovac COVID shots induces stronger respon..
RE
09/01SINOVAC BIOTECH : North Korea turns down Sinovac COVID-19 vaccine doses - WSJ
RE
08/24SINOVAC BIOTECH : COVID-19 booster shots should follow after China inoculates mo..
RE
08/23São Paulo City Will Require Proof of Vaccination to Enter Shops, Bars
DJ
08/19SINOVAC BIOTECH : U.N. facility allocates 3 mil. doses of China's vaccine to N. ..
AQ
08/17UK regulator approves Moderna COVID-19 shot for 12 to 17-year-olds
RE
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,5%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED9.25%102 521
WUXI BIOLOGICS (CAYMAN) INC.19.75%67 077
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 329
BIOGEN INC.22.60%44 738
ALEXION PHARMACEUTICALS, INC.0.00%40 336